Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
1984 1
1985 3
1986 6
1987 1
1988 3
1989 8
1990 4
1991 13
1992 33
1993 51
1994 101
1995 75
1996 88
1997 65
1998 65
1999 73
2000 74
2001 57
2002 78
2003 70
2004 100
2005 68
2006 74
2007 60
2008 56
2009 72
2010 96
2011 97
2012 77
2013 74
2014 76
2015 85
2016 65
2017 82
2018 91
2019 104
2020 143
2021 177
2022 187
2023 157
2024 50

Text availability

Article attribute

Article type

Publication date

Search Results

2,619 results

Results by year

Filters applied: . Clear all
Page 1
Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.
Chihara D, Arons E, Stetler-Stevenson M, Yuan CM, Wang HW, Zhou H, Raffeld M, Xi L, Steinberg SM, Feurtado J, James L, Wilson W, Braylan RC, Calvo KR, Maric I, Dulau-Florea A, Kreitman RJ. Chihara D, et al. J Clin Oncol. 2020 May 10;38(14):1527-1538. doi: 10.1200/JCO.19.02250. Epub 2020 Feb 28. J Clin Oncol. 2020. PMID: 32109194 Free PMC article. Clinical Trial.
PURPOSE: Single-agent purine analog, usually cladribine, has been the standard first-line therapy of hairy cell leukemia (HCL) for 30 years. ...CONCLUSION: Achieving MRD-free CR of HCL after first-line cladribine is greatly enhanced by concurrent rituximab and less …
PURPOSE: Single-agent purine analog, usually cladribine, has been the standard first-line therapy of hairy cell leukemia (HCL) for 30 …
Cladribine (Mavenclad) for multiple sclerosis.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2019 Jul 29;61(1577):118-120. Med Lett Drugs Ther. 2019. PMID: 31381552 Review. No abstract available.
Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis.
Nabizadeh F, Mohamadi M, Rahmani S, Rajabi R, Afrashteh F, Najdaghi S, Mirmosayyeb O. Nabizadeh F, et al. Neurol Sci. 2023 Sep;44(9):3045-3057. doi: 10.1007/s10072-023-06794-w. Epub 2023 Apr 17. Neurol Sci. 2023. PMID: 37062787 Free PMC article. Review.
The pooled SMD for EDSS before and after treatment was - 0.54 (95%CI: - 1.46, 0.39). Our analysis showed that the PFS after cladribine use is 79% (95%CI 71%, 86%). Also, 58% of patients with MS who received cladribine remained relapse-free (95%CI 31%, 83%). ...Combi …
The pooled SMD for EDSS before and after treatment was - 0.54 (95%CI: - 1.46, 0.39). Our analysis showed that the PFS after cladribine …
Cladribine: mechanisms and mysteries in multiple sclerosis.
Jacobs BM, Ammoscato F, Giovannoni G, Baker D, Schmierer K. Jacobs BM, et al. J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1266-1271. doi: 10.1136/jnnp-2017-317411. Epub 2018 Jul 10. J Neurol Neurosurg Psychiatry. 2018. PMID: 29991490 Review.
The pharmacology of cladribine explains how it is selectively toxic towards lymphocytes. ...CONCLUSIONS: Cladribine is a safe and effective form of induction therapy for relapsing MS. ...
The pharmacology of cladribine explains how it is selectively toxic towards lymphocytes. ...CONCLUSIONS: Cladribine is a safe …
Cladribine Tablets: A Review in Relapsing MS.
Deeks ED. Deeks ED. CNS Drugs. 2018 Aug;32(8):785-796. doi: 10.1007/s40263-018-0562-0. CNS Drugs. 2018. PMID: 30105527 Free PMC article. Review.
Cladribine is a deoxyadenosine analogue prodrug that preferentially depletes lymphocytes, key cells underlying multiple sclerosis (MS) pathogenesis. Cladribine tablets (Mavenclad()) represent the first short-course oral disease-modifying drug (DMD) for use in MS. .. …
Cladribine is a deoxyadenosine analogue prodrug that preferentially depletes lymphocytes, key cells underlying multiple sclerosis (MS …
Cladribine to Treat Relapsing Forms of Multiple Sclerosis.
Giovannoni G. Giovannoni G. Neurotherapeutics. 2017 Oct;14(4):874-887. doi: 10.1007/s13311-017-0573-4. Neurotherapeutics. 2017. PMID: 29168160 Free PMC article. Review.
An oral formulation of cladribine has been developed to be given as short courses over two annual cycles. ...Oral cladribine is effective in relapsing forms of multiple sclerosis. As a selective immune reconstitution therapy (SIRT), cladribine acts as a short …
An oral formulation of cladribine has been developed to be given as short courses over two annual cycles. ...Oral cladribine i …
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group. Giovannoni G, et al. N Engl J Med. 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089960 Free article. Clinical Trial.
BACKGROUND: Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. ...CONCLUSIONS: Treatment with cladribine tablets significantly reduced relapse rates, the risk of disability progression, and MRI measures of disease activity at 96 …
BACKGROUND: Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. ...CONCLUSIONS: Treatment with …
Cladribine (2-chlorodeoxyadenosine).
Beutler E. Beutler E. Lancet. 1992 Oct 17;340(8825):952-6. doi: 10.1016/0140-6736(92)92826-2. Lancet. 1992. PMID: 1357355 Review. No abstract available.
Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Lambe T, Duarte R, Mahon J, Nevitt S, Greenhalgh J, Boland A, Beale S, Kotas E, McEntee J, Pomeroy I. Lambe T, et al. Pharmacoeconomics. 2019 Mar;37(3):345-357. doi: 10.1007/s40273-018-0718-2. Pharmacoeconomics. 2019. PMID: 30328051 Free PMC article. Review.
As part of the single technology appraisal process, the National Institute for Health and Care Excellence invited Merck to submit evidence for the clinical and cost effectiveness of cladribine tablets (cladribine) for the treatment of relapsing-remitting multiple sc …
As part of the single technology appraisal process, the National Institute for Health and Care Excellence invited Merck to submit evidence f …
Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?
Qasrawi A, Bahaj W, Qasrawi L, Abughanimeh O, Foxworth J, Gaur R. Qasrawi A, et al. Ann Hematol. 2019 Mar;98(3):561-579. doi: 10.1007/s00277-018-3562-8. Epub 2018 Nov 23. Ann Hematol. 2019. PMID: 30470874 Review.
Recent clinical trials and retrospective studies explored the addition of cladribine to standard induction chemotherapy for AML. Some of these studies showed higher rates of complete remission, and one showed improved survival. In this review, we will discuss the antileuke …
Recent clinical trials and retrospective studies explored the addition of cladribine to standard induction chemotherapy for AML. Some …
2,619 results

Searches related to "cladribine"